SI · Shoulder Innovations, Inc.
$19.60
+0.59 (+3.10%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$353.71M
Shares
20.82M
Volume · Oct 5
148.09K
Avg daily vol (3M)
117.18K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.60
Open$18.81
Day$18.74–20.03
52W close$11.01–24.25
Avg vol 30d123K
Short int420K · 2.0% float · 4.7d
Short vol74%
Last earningsAug 6, 2026
DataJul 2025–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 20, 2026
Est · unconfirmed
· in 2 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$60.05M
Trailing 12 months
Net income (TTM)
−$35.03M
Trailing 12 months
Revenue growth YoY
+56.0%
Year over year
Operating margin
-58.5%
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 1,115.8%
FCF yield
-13.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$9.65M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17,781.0%
Year over year · more shares
Price change (1Y)
+58.3%
Trailing year
Short interest
2.0%
Latest settlement · 4.7 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Shoulder Innovations reported Q2 2026 net revenue of $17.2 million, up 56% year-over-year, with gross margin expanding to 78.3%, and raised full-year 2026 revenue guidance to $67–$69 million from $65–$68 million while highlighting an accelerating pipeline that includes a planned H1 2027 FDA submission for its INSET NEO robotic system.
Bullish
- + Q2 net revenue grew 56% year-over-year to $17.2 million, with 2,238 implant units sold (~50% growth) and ASP up 5% to $7,674.
- + Full-year 2026 revenue guidance was raised to $67–$69 million (42–46% growth) from $65–$68 million (37–44% growth), with management citing high conviction.
- + New-customer additions accelerated sequentially in Q2 and all territories grew year-over-year, with the majority delivering more than 80% growth.
- + Closed new credit facilities of up to $50 million with Stifel Venture Banking, refinancing existing debt and adding undrawn working-capital capacity.
Bearish
- − Operating loss widened to $10.0 million from $5.9 million year-over-year as operating expenses scaled faster than revenue.
- − Q3 SG&A as a percentage of revenue is expected to increase from Q2 before declining in Q4, signaling near-term margin pressure.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
−3%
below
RSI (14)
56
neutral
MACD trend
Positive
52-week position
65%
mid-range
Momentum
relative strength
1-month return
−4%
trailing
6-month return
+31%
trailing
YTD return
+37%
this year
Relative strength
+19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+24% holders QoQ · +24 funds added
Insider flow
Distributing
Net -$4.6M over 90 days · 100% sells
Short interest
Rising
2.02% of float · ▲ +39.2% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 1-yr high, broad support
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+50%
Y/Y
Gross margin
77%
contracting
EPS growth
+98%
Y/Y
Free cash flow
$-36.0M
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Net revenue
· full year 2026
Initiated
$67M – $69M
prior FY $47.32M
midpoint +43.7% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
65%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $20 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+24% holders QoQ · +24 funds added
Insider flow
Distributing
Net -$4.6M over 90 days · 100% sells
Short interest
Rising
2.02% of float · ▲ +39.2% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
72 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $20 · 65%
Range high $24
vs 200-day avg +18%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$14.98M | six months ended June 30, 2026 | — |
| average selling price of our implant systems | $7,674 | the second quarter | — |
| total implant systems sold | 2,238 | the second quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SI | +9.2% | -3.5% | +30.6% | +3.7% | +37.1% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +8.0% | -4.1% | +19.0% | +2.1% | +23.4% |